Our DMRS may be useful for the clinician-patient risk discussion for patients with diabetes to help communicate risks for total CVD as well as its individual components and the need for initiation or intensification of tailored therapeutic approaches (eg, statins and antihypertensives for ASCVD and stroke prevention, antihypertensives and SGLT2 inhibitors for HF prevention), as well as to motivate physicians and patients alike to be more motivated to achieve targets for HbA1c, LDL-C, BP, and other measures if not adequately controlled. This evidence concerns the gene SLC5A2 and diabetes mellitus.